However, clinical studies have unexpectedly reported that the response rate to these drugs is high in patients with non-small cell lung cancer (NSCLC) but limited in patients with colorectal cancer 10-12, suggesting the intertumor heterogeneity in KRAS-mutant cancers. This evidence concerns the gene KRAS and non-small cell lung carcinoma.